Liu, J., Zhou, G., Zhang, L. & Zhao, Q. Building potent chimericantigen receptor T cells with CRISPR genome editing. Frontiers in Immunology (2019) doi:10.3389/fimmu.2019.00456.
Nie, Y. et al. Mechanisms underlying CD19-positive ALLrelapse after anti-CD19 CAR T cell therapy and associated strategies. Biomarker Research (2020) doi:10.1186/s40364-020-00197-1.
Zhao, J., Lin, Q., Song, Y. & Liu, D. Universal CARs, universalT cells, and universal CAR T cells. Journal of Hematology and Oncology (2018) doi:10.1186/s13045-018-0677-2.
Subklewe, M., Von Bergwelt-Baildon, M. & Humpe, A. ChimericAntigen Receptor T Cells: A Race to Revolutionize Cancer Therapy. Transfusion Medicine andHemotherapy (2019) doi:10.1159/000496870.
Chicaybam, L. et al. Overhauling car t cells to improveefficacy, safety and cost. Cancers (2020) doi:10.3390/cancers12092360.
Zhang, J. et al. Development and clinical evaluation of non-viralgenome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkinlymphoma. medRxiv 2020.09.22.20199786; doi: //doi.org/10.1101/2020.09.22.20199786
Eyquem, J. et al. Targetinga CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature (2017) doi:10.1038/nature21405.